Precision medicine has long promised to match the right treatment to the right patient. CAR-T cell therapy, gene editing, and advanced cell therapies take that promise considerably further—not by targeting symptoms more accurately, but by intervening at the molecular level where disease originates. A patient’s own T cells can be reprogrammed to recognise and destroy […]
Pharmaceutical development has operated for generations under a model that tolerates significant uncertainty as an unavoidable feature of the process. Candidates advance through development stages carrying unresolved questions about formulation robustness, process variability, and stability—questions that surface as batch failures, regulatory requests for additional data, or post-approval manufacturing difficulties that erode both margin and market
The pharmaceutical industry’s competitive frontier has quietly shifted. For decades, advantage was defined almost entirely by what happened inside the laboratory—the quality of targets selected, the ingenuity of molecular design, the rigour of preclinical science. Those capabilities remain foundational. What has changed is the weight carried by everything that happens after a molecule is identified:
Traditional drug discovery has operated for decades under an economics model that would be considered untenable in almost any other industry. Pipelines crowded with candidates that fail in late-stage trials, targets pursued on biological intuition rather than rigorous evidence, and chemistry processes that consume years before a molecule reaches its first human test—all sustained by
Drug discovery has historically been an exercise in expensive attrition. The conventional model—identify a disease target, screen compounds, optimise leads, test preclinically, and hope clinical trials vindicate the original hypothesis—is sequential, slow, and brutally uncertain. Candidates fail at every stage, often because the biological target was poorly validated long before a molecule was synthesised. The
From Academic Foundations to Applied Intelligence: Dr. Murali Addepalli’s Journey in Advancing Biologics Toward Patient CareWork across NIH research, industry biologics programs, and emerging AI applications in drug discovery. Most researchers dream of discovering breakthrough therapies. Dr. Murali Addepalli set himself a different, more audacious goal: actually, getting one to patients. Not publishing elegant papers about potential therapeutics that remain trapped in
From IIT Bombay to continuous manufacturing platforms—how one leader’s 18-year journey across Amgen, Regeneron, and Indian biotech is redefining what’s possible in biologics development Most biotechnology leaders pick a lane: deep technical expertise or broad operational leadership, Big Pharma scale or biotech agility, innovator molecules or biosimilars execution. Dr. Abhishek Mathur has systematically refused to
Brazil imports billions worth of medicines from India annually. Now, Health Minister Alexandre Padilha wants to fundamentally rewrite that relationship. Rather than merely purchasing finished generics and active pharmaceutical ingredients from Indian manufacturers, Brazil seeks strategic partnerships to establish local production facilities, transfer technology, and build genuine pharmaceutical manufacturing capacity within Brazilian borders. This dramatic
Brazil to India: Stop Selling Us Drugs, Help Us Make Them Instead Read More »
India controls just 2 percent of the $400 billion global nutraceutical market. Yet FSSAI officials project the sector will outpace pharmaceuticals by tenfold—a claim that would sound audacious were it not grounded in converging forces rarely seen simultaneously in a single industry. Post-pandemic health consciousness has permanently shifted consumer behaviour away from reactive medicine towards
From 2% to Superpower: India’s Nutraceutical Sector Eyes Its $65 Billion Moment Read More »
Uttar Pradesh’s inaugural Pharma Conclave 1.0 at Lucknow’s Taj Mahal Hotel on February 3, 2026, assembled India’s pharmaceutical royalty—Sun Pharma‘s Dilip Shanghvi, Dr Reddy’s Satish Reddy, Zydus‘ Pankaj Patel, Mankind‘s Ramesh Juneja—for what amounts to a declaration of intent: India’s most populous state wants to become its pharmaceutical powerhouse, wresting leadership from established hubs through
